TY - JOUR
T1 - Monitoring for human papillomavirus vaccine impact among gay, bisexual, and other men who have sexwith men-United States, 2012-2014
AU - Meites, Elissa
AU - Gorbach, Pamina M.
AU - Gratzer, Beau
AU - Panicker, Gitika
AU - Steinau, Martin
AU - Collins, Tom
AU - Parrish, Adam
AU - Randel, Cody
AU - McGrath, Mark
AU - Carrasco, Steven
AU - Moore, Janell
AU - Zaidi, Akbar
AU - Braxton, Jim
AU - Kerndt, Peter R.
AU - Unger, Elizabeth R.
AU - Crosby, Richard A.
AU - Markowitz, Lauri E.
N1 - Publisher Copyright:
© The Author 2016.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background. Gay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact. Methods. During 2012-2014, MSM aged 18-26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assay. Results. Among 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity. Discussions. Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.
AB - Background. Gay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact. Methods. During 2012-2014, MSM aged 18-26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assay. Results. Among 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity. Discussions. Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.
KW - Epidemiological monitoring
KW - Homosexuality male
KW - Papillomavirus infections
KW - Papillomavirus vaccines
UR - http://www.scopus.com/inward/record.url?scp=84988978316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988978316&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiw232
DO - 10.1093/infdis/jiw232
M3 - Article
C2 - 27296847
AN - SCOPUS:84988978316
SN - 0022-1899
VL - 214
SP - 689
EP - 696
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -